Meetings - The ASCO Post

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...

Cardio-oncology

By Susan Reckling, MA / August 25, 2024 / 2024 Debates and Didactics in Hematology and Oncology

An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate

At the 2024 Debates and Didactics in Hematology and Oncology Conference, sponsored by Emory’s Winship Cancer Institute, cardiologist-by-training Anant Mandawat, MD, FACC, briefly reviewed how the emer...

Leukemia

By Caroline Helwick / September 10, 2024 / 2024 Debates and Didactics in Hematology and Oncology

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

With the introduction of tyrosine kinase inhibitors, chronic myeloid leukemia (CML) has become a chronic disease for most patients. Furthermore, we now know that some patients can successfully stop tr...

2024 Debates and Didactics in Hematology and Oncology

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

An Integrated Approach to Treating Cancer and Cardiovascular Disease: When Oncologists and Cardiologists Collaborate

Discontinuation of CML Therapy: Which Patients Are Ideal Candidates?

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?

International Cancer Organizations Present Collaborative Work During Oncology Event in China

Is There a Role for Neoadjuvant Chemotherapy in HR-Positive, HER2-Negative Early Breast Cancer?

Suicide-Related Mortality in Male AYA Cancer Survivors

Four-Year Asian Subpopulation Data From the CheckMate 816 Trial of Neoadjuvant Nivolumab Plus Chemotherapy in Resectable NSCLC